NCT06800053 FOCUS ON US: Adapting the FOCUS Program for Sexual and Gender Minority (SGM) Cancer Patients and Caregivers
| NCT ID | NCT06800053 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Charles Kamen |
| Condition | Cancer Support |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-09-04 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2025-09-04 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Our aim for this study is to assess the feasibility and acceptability and explore potential outcomes of the adapted FOCUS On Us intervention in a two-arm pilot trial. The investigators will randomize 80 sexual and/or gender minority (SGM; e.g., lesbian, gay, bisexual, transgender, queer, etc.) cancer patients and their ≥80 informal caregivers (total N≥160) to either FOCUS On Us (adapted from the evidence-based FOCUS program) or a waitlist control.
Eligibility Criteria
Inclusion Criteria: Patients must: 1. have been diagnosed or had a biochemical recurrence or progression of any invasive (e.g., Stage ≥1) cancer within the past 24 months; 2. have at least one informal (unpaid) caregiver willing to participate in the program; 3. identify as a sexual and/or gender minority (SGM) OR have a caregiver who identifies as SGM (e.g., either the patient or caregiver(s) must be SGM); 4. be age 18 or older; 5. be able to complete all written and oral components of the study in English; 6. provide informed consent; 7. live in the United States. Caregivers must: 1. self-report having provided support for a cancer patient as an informal (unpaid) caregiver; 2. have a cancer patient for whom they provided support willing to participate in the program; 3. identify as a sexual and/or gender minority (SGM) OR have provided support to a patient who identifies as SGM (e.g., either the patient or caregiver(s) must be SGM); 4. be age 18 or older; 5. be able to complete all written and oral components of the study in English; 6. provide informed consent; 7. live in the United States
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06800053 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Cancer Support. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06800053 currently recruiting?
Yes, NCT06800053 is actively recruiting participants. Contact the research team at Lelaina_nagle@urmc.rochester.edu for enrollment information.
Where is the NCT06800053 trial being conducted?
This trial is being conducted at Detroit, United States, Rochester, United States.
Who is sponsoring the NCT06800053 clinical trial?
NCT06800053 is sponsored by Charles Kamen. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.